Please use this identifier to cite or link to this item:
10.2147/opth.s8011
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Teus, Miguel A. | - |
dc.contributor.author | Miglior, Stefano | - |
dc.contributor.author | Laganovska, Guna | - |
dc.contributor.author | Volksone, Lasma | - |
dc.contributor.author | Romanowska-Dixon, Bozena | - |
dc.contributor.author | Gos, Roman | - |
dc.contributor.author | Holló, Gábor | - |
dc.date.accessioned | 2022-01-20T15:15:01Z | - |
dc.date.available | 2022-01-20T15:15:01Z | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | Teus , M A , Miglior , S , Laganovska , G , Volksone , L , Romanowska-Dixon , B , Gos , R & Holló , G 2009 , ' Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension ' , Clinical Ophthalmology , vol. 3 , no. 1 , pp. 629-636 . https://doi.org/10.2147/opth.s8011 | - |
dc.identifier.issn | 1177-5467 | - |
dc.identifier.uri | https://dspace.rsu.lv/jspui/handle/123456789/7240 | - |
dc.description.abstract | Purpose: To compare the intraocular pressure- (IOP-) lowering efficacy of fixed combinations travoprost 0.004%/timolol 0.5% and dorzolamide 2%/timolol 0.5% in patients with ocular hypertension or open-angle glaucoma. Methods: In this prospective, multicenter, double-masked, randomized clinical trial, 319 qualifying patients received either travoprost/timolol once daily in the morning (n = 157) or dorzolamide/timolol twice daily (n = 162). IOP was assessed morning and evening at 2 and 6 weeks. The primary outcome measure was mean diurnal IOP. Results: Baseline mean IOP values were similar between groups. Mean pooled diurnal IOP was significantly lower in the travoprost/timolol group (16.5 mmHg ± 0.23) than in the dorzolamide/timolol group (17.3 mmHg ± 0.23; P = 0.011). Mean IOP was significantly lower in the travoprost/timolol group compared to the dorzolamide/timolol group at the 9 AM time point both at Week 2 (P = 0.006) and Week 6 (P = 0.002). The travoprost/timolol combination produced mean IOP reductions from baseline of 35.3% to 38.5%, while the dorzolamide/timolol combination produced mean IOP reductions from baseline of 32.5% to 34.5%. Conclusions: The fixed combination travoprost 0.004%/timolol 0.5% dosed once daily in the morning demonstrated superior mean diurnal IOP-lowering efficacy compared to dorzolamide 2%/timolol 0.5% dosed twice daily in patients with ocular hypertension or open-angle glaucoma. | en |
dc.format.extent | 8 | - |
dc.format.extent | 224837 | - |
dc.language.iso | eng | - |
dc.relation.ispartof | Clinical Ophthalmology | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.subject | Dorzolamide | - |
dc.subject | Fixed combination | - |
dc.subject | Glaucoma | - |
dc.subject | IOP-lowering therapy | - |
dc.subject | Timolol | - |
dc.subject | Travoprost | - |
dc.subject | 3.2 Clinical medicine | - |
dc.subject | 1.1. Scientific article indexed in Web of Science and/or Scopus database | - |
dc.subject | Ophthalmology | - |
dc.title | Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension | en |
dc.type | /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article | - |
dc.identifier.doi | 10.2147/opth.s8011 | - |
dc.identifier.url | http://www.scopus.com/inward/record.url?scp=77949891677&partnerID=8YFLogxK | - |
dc.description.status | Peer reviewed | - |
Appears in Collections: | Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Efficacy_and_safety_of_travoprost.pdf | 219.57 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.